US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech ...
Jiangsu Hengrui and Kailera reveal Phase II data for HRS9531, a GLP-1/GIP dual agonist showing 21.1% placebo-adjusted weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback